
Charlotte-Paige Melanie Rolle MD
Clinical Fellow in Medicine, Brigham and Women's Hospital
Join to View Full Profile
1707 N Mills AveOrlando, FL 32803
Phone+1 407-647-3960
Fax+1 407-367-0856
Dr. Rolle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Emory University School of MedicineFellowship, Infectious Disease, 2017
- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2010 - 2014
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2010
Certifications & Licensure
- FL State Medical License 2017 - 2027
Clinical Trials
- Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF Start of enrollment: 2020 Oct 05
Roles: Contact, Sponsor-Investigator, Principal Investigator
Publications & Presentations
PubMed
- Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppresse...Charlotte-Paige Rolle, Jeffrey Garrett, Jamie Castano, Vu Nguyen, Kiran Patel
Medicine. 2025-03-07 - Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials.Charlotte-Paige Rolle, José R Arribas, Roberto Ortiz, Mark Underwood, Chris M Parry
Open Forum Infectious Diseases. 2025-03-01 - Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial.Joseph C Gathe, Edwin Dejesus, Moti N Ramgopal, Charlotte-Paige Rolle, Otto O Yang
Journal of Acquired Immune Deficiency Syndromes. 2025-02-20
Press Mentions
- Treatment-Related Early Discontinuations and Adverse Events Among Newly Diagnosed People Living with HIV Initiating Integrase Inhibitors in a Real-World SettingFebruary 1st, 2023
- Two-Drug Dolutegravir Treatment Noninferior to 3/4 Drug RegimenJuly 22nd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: